the new doh pmtct policy challenges and opportunities
DESCRIPTION
The New DOH PMTCT Policy Challenges and Opportunities. A H Coovadia ECHO Enhancing Childhood HIV Outcomes Department of Paediatrics and Child Health Coronation Women and Children Hospital University of The Witwatersrand. Overview. PMTCT - Background The Old PMTCT Policy - PowerPoint PPT PresentationTRANSCRIPT
The New DOH PMTCTPolicy
Challenges and Opportunities
A H CoovadiaECHO
Enhancing Childhood HIV Outcomes Department of Paediatrics and Child HealthCoronation Women and Children Hospital
University of The Witwatersrand
Overview PMTCT - Background The Old PMTCT Policy Where are we with PMTCT today ? The NSP (2007-2011) The New Revised PMTCT Policy PMTCT – The ‘Gateway Programme’ Challenges and Opportunities
Background 55% of all HIV-1 positive adults are
women of child bearing age. Seroprevalence rates among
pregnant women exceeds 30% in many urban populations in sub-Saharan Africa
MTCT Rates ~10 - 30% in non-breastfeeding
population of HIV-1 positive women in more developed countries
25 -45% in breast-feeding populations in Africa
intrapartum67%
in utero33%
Timing of transmission in Non breast-feeding
Transmission in Children
breastfeeding30%
intrapartum60%
in utero10%
Timing of transmission Breastfeeding
Risk Factors for Mother-to-child-transmission
High maternal viral load
Low maternal CD4 count
Vaginal delivery
Premature rupture of membranes
Breast milk
Risk Factors for Mother-to-child-transmission
chorioamnionitis low birth weight of the baby the first twin born unprotected intercourse with an HIV-
infected partner IV drug abuse STI’s
History of PMTCT and ARV interventions
ACTG 076 1994, AZT to mother from 2nd trimester,
IV during labour and delivery, 6 weeks to infant; transmission reduced from 25%-8%
Shorter course therapies sought Thai regimen PETRA
HIVNET 012 Nevirapine one dose to mother and one
dose to baby (transmission reduced to 13%)
Number of cases
PACTG 076 USPHS AZT Recommendations
80% declin
e
What did we know and when did we know it? Perinatal HIV Clinical Trial Results
1994 U.S. AZT Trial ACTG 076• 67% reduction in transmission
1998 Thai Bangkok short AP/IP AZT trial
• 50% reduction in transmission
1998 Cote d‘Ivoire short AP/IP AZT trials
• 37% reduction in transmission (breastfeeding)
1999 PETRA AZT/3TC trial (6 wk results)• 50% reduction with longest arm. • 38% reduction with the IP/PP arm
1999 Uganda 2-dose IP/PP NVP trial (HIVNET 012)• 47% reduction in transmission (breastfeeding)
1994 2004
2000 ThailandLong vs short AZT regimens
• 4% TR in LL (non BF)
2002 Cote d’Ivoire DITRAME +
• 6.2% TR with AZT & IP/PP NVP
2004 Thailand PHPT• 1.9% AZT + NVP
2003 DITRAME + 1201.1• 4.7% TR with AZT/3TC &
IP/PP NVP
PMTCT: The four-pronged strategy
• Primary prevention of HIV in parents-to-be
• Prevention of unwanted pregnancies
• Prevention of transmission from HIV-infected mother to infant
• Appropriate treatment and care
SA pMTCT Programme2001 - 2007
Nevirapine as single dose (sd) administration Dose= 1 tablet to mum at onset of labour
and a dose to baby within 72 hours after birth
Provision of infant formula for six months to mothers choosing this option.
NVP prevents MTCT by ~50% (Transmission Rates of approximately 10%)
Non-pregnancy related infections mainly HIV, TB and Pneumonia were the leadingcause of death in 38% of women
However probably an underestimate asonly 46% of women who died were tested for HIV, and 78% of those tested were HIV positivePMTCT is an opportunity to save the
lives of mothers and not only babies !
National Antenatal Testing Rate was 75%
compared with 45% (2005/6)HIV prevalence rate
amongst ANC attendees = 29%
Compared with 30.2% (2005/6)Percentage of Women
receiving Nevirapine was 61%
Compared with 52% (2005/6)Percentage of Babies
receiving Nevirapine was 45%
Lower than 2005/6 BUT more likely reflecting better quality data
29.5
30.229.1
National HIV and Syphilis Prevalence Survey 2006
The National Strategic Plan2007 - 2011
NSP GoalsKEY Priority Area 1 – PREVENTION
Reduce the rate of new infections by 50% by 2011
Section 3 of the Key Priority area 13.1 Broaden existing mother to child transmission
services to include other related services and target groups3.2 Scale up coverage and improve quality of PMTCT to reduce MTCT to less than 5%”
NSP TargetsObjective Intervention 5-year target Lead
Agency
2007 2008 2009 2010 2011
3.2:Scale up coverage and improve quality of PMTCT to reduce MTCT to less than 5 %
Increase the proportion of public sector antenatal services providing PMTCT
85 % 95 %
100 % 100 % 100 % DOH
Increase proportion of pregnant women tested through implementation of provider initiated VCT for all pregnant women
70 % 85 % 90 % 95 % 95 % DOH
Develop an policy and guidelines on VCT in pregnancy including consideration of provider initiated testing, and frequency of testing
Develop & implement
Annual review
Annual review
Annual review
Annual review
DOH, NGOs,DoE
Increase the proportion of the estimated population of HIV-infected pregnant women in need who receive PMTCT services
60 % 70 % 80 % 90 % 95 % DOH
The New Revised PMTCT Policy2008
‘Routine offer of VCT’ (Provider Initiated) Addition of AZT (Dual Therapy) Emphasis on getting CD4 counts on all
pregnant women to start HAART in pregnancy (CD4 < 200 OR WHO stage 4)
Infant Feeding Options – better guidance Emphasis on infant diagnosis at 6 weeks
SA pMTCT Programme2008 DUAL THERAPY
Women who need ARVs – get put onto this ASAP (CD4 count less than 200)
FOR WOMEN WITH CD4 COUNTS ABOVE 200 OR IF NOT YET ON ARVs (I.E ALL WOMEN)
Mother - AZT during pregnancy from 28 weeks gestation + single tablet Nevirapine in Labour
Baby – Single dose Nevirapine + AZT for 7 days (and in some cases upto 28 days)
Able to reduce MTCT to 5% with new policy !
AZT TO BABY FOR 4 WEEKS IF:
Mother received no PMTCT
Mother received only nevirapine for PMTCT
Less than 4 weeks of AZT/HAART taken by mother
Mother diagnosed for the first time in labour or postpartum – AZT to baby best given within 12 hours of birth
One out of four babies (25%) born to all HIV positive mothers will acquire HIV from their mother ( if no intervention is offered )
That means at least 75% of babies are uninfected at birth!
Mother to Child Transmission
5% Infected
PMTCT RATESOf all HIV Infected Women
75 % HIV Negative Babies
25 % HIV Infected BabiesWhere no intervention
10% Infected Old policySd NVPNew policyAZT + Sd NVP
95 % HIV Negative Babies !
First StepTesting
Testing
SCREENING HIV TEST
SCREENING POSITIVE
SCREENINGNEGATIVE
NEGATIVECONFIRMATORY HIV TEST
CONFIRMATORYPOSITIVE
CONFIRMATORY NEGATIVE
INDETERMINATEFINAL RESULTPOSITIVE
SEND FOR HIV ELISA
POSITIVE / NEGATIVE ELISA
FINAL RESULT
INDETERMINATE ELISASEND FOR HIV DNA PCR
(diagnostic PCR)
REPEAT TEST AT AROUND 34 WEEKS
HbCD4
GestationWeek ?
Management of HIV infected Pregnant WomanFirst Visit (WHO stage I-III)
If < 28 weeksOr
Hb <8g/dlDo NOT Start
AZT
If 28 wks or more
Hb ≥8g/dlStart AZT300mg BD
CD4WHOStage
Assessment of HIV infected Pregnant WomanSecond Visit
CD4 < 200 OR
WHO Stage IV
HAARTIf previously on AZTSwitch to 3TC/d4T/NVP
CD4 > 200 OR
WHO Stage I-III
PMTCT RegimenIf ≥ 28weeksAZT until Delivery
LABOUR AND DELIVERY At onset of labour, woman to take 600mg AZT (2
tablets) stat plus 200mg sd (1 tablet) nevirapine. If Nevirapine already taken previously with false
labour, do not repeat nevirapine dose and neonate receives standard post exposure prophylaxis.
Continue AZT 300mg 12 hourly at the usual times until the neonate is delivered.
Mother on HAART, continue treatment as usual during labour.
POSTNATAL CAREBaby: Nevirapine 0.6 ml as soon as possible after
delivery (under 2.5kg give 0.2ml/kg), plus
AZT 4mg/kg 12 hourly for 7 days or 28 days (premature <35 weeks 2mg/kg) Above the same for women on AZT or on
HAART
Enquire about feeding options from the mother
Babies Requiring 28 days ofAZT
Where mother had no ARVS at all during antenatal period or labour i.e unbooked
Mother had < 4 weeks of AZT or Mother had < 4 weeks of HAART Mother received only sd NVP
What about the women testing Negative ?
Repeat HIV testing at or around 34 weeks of gestation
About 5% of women will seroconvert during pregnancyHIV NEG ----------------- HIV POS
What about the women who haven’t been tested ?
No women should leave a healthcare facility without beingoffered an HIV test.
Not doing so is tantamount to being negligentRemember too our responsibility to both mother and the child
Labour Ward Postnatal Ward
Challenges to Success of the Programme
Political leadership Testing rates below target Adequacy of human resources (e.g trained counsellors) Information transfer between facilities. Stigma Drug supply – NVP + AZT (no stock outs) No widespread campaign explaining benefits of programme Lack of integration with other services such as family
planning/CCMT/EPI Community and NGO involvement largely lacking Not seen as priority programme by healthcare facilities that
have other competing demands Public sector focussed rather than larger public health concern,
where only addressing attendees to the public health service
Which Services need integration ? VCT – Family Planning VCT – PMTCT PMTCT – CCMT (ARV sites) PMTCT – Infant Diagnosis and Follow up
(IDFU) Infant Diagnosis and Paediatric ARV site EPI – IDFU TB - CCMT STI - CCMT
Meeting the challenges Political Commitment Increase effective coverage - PMTCT programme in 100% of healthcare facilities
providing ANC Testing strategy needs revisiting – Provider initiated TC Adequate staffing with role clarification and systems improvement to enable
better coverage of all women. Prioritization of programme within healthcare facility. All staff at facilities must
understand importance of the programme. Programme leadership with dedicated and responsible team who monitor
progress in on-going manner i.e M&E at local level. Integration of PMTCT with CCMT services to enable smooth transfer of patients
needing treatment Community education and involvement in getting testing rates up. Mass media and educational campaigns to raise awareness of the programme and
it’s benefits. INFANTS - Need to ensure that ALL HIV exposed infants reap the benefits of an
enhanced PMTCT programme, which would include Abandoned infants (upto 50% have been noted to have had HIV exposure) Infants whose mothers are indisposed – death, coma, serious post-partum illness, mental
confusion Infants whose mothers refuse testing - Infants whose mothers refuse any intervention despite knowing their status
Opportunities Improve overall maternal antenatal care and outcomes
Through training on basic ANC Reduction in maternal mortality (NCCEMD) Improvement in basic infrastructure/equipment
Improve HIV testing rates amongst adults (women and men)
Expedited entry onto ARVs for women with low CD4 counts
Increasing access points for ARVs for patients Drastically reducing numbers of infected infants Establishing follow up for infants with early diagnosis
and treatment if needed Decreasing orphanhood
PMTCT‘The Gateway Programme’
Thesaurus Entry Opening Access First step Opportunity Chance
Longman Dictionary An opening in a fence or way etc, across which a
gate may be put A way of finding e.g Hardwork is the gateway to
success
5% Infected
95 % HIV Negative Babies
What are we aiming for ?
PMTCT95% HIV negatives
+ves
Early IdentificationOf all infected infants
Early initiation of HAARTin infants
Decreasenumberof infectedChildrenIn SA
Decrease morbidity And mortality in HIVinfected Children in
SA
Early IdentificationOf Sick Women
Decrease morbidity
And mortality in HIV
infected Women in SA
Decrease number of infected
WomenIn SA
References SA National DOH PMTCT Policy (2008) District Health Barometer (HST 2006/7) Every Death Counts Report Lancet – Every Death Counts
Would like to thank Prof James McIntyre for use of some slides.